Management of Increased Intraocular Pressure in Patients Taking Prednisone

Risk Factors and Monitoring

• Higher frequency of topical steroid administration (≥2 drops/day) is a strong risk factor for IOP elevation 1
• Longer duration of therapy increases the risk of complications 1
• Regular monitoring for elevated IOP is essential when using prednisolone eye drops, especially when treatment extends beyond a few weeks 1
• For patients on topical steroids, periodic examinations are necessary to monitor ocular status and check for corticosteroid-related side effects such as elevated IOP 2, 3
• IOP should be checked at regular intervals in patients using long-term topical corticosteroids 4
• Consider baseline IOP measurement before initiating steroid therapy to identify pre-existing elevated IOP 5

Prevention and Management Strategies

• Use the minimum effective dose and duration of steroid therapy 1
• Consider alternative steroid formulations with lower IOP risk, such as prednisolone acetate 1% which is preferred over difluprednate due to lower risk of steroid-induced IOP elevation 6
• Corticosteroids with poor ocular penetration (e.g., fluorometholone) or site-specific corticosteroids (e.g., loteprednol) may be less likely to result in elevated IOP 2
• For conditions requiring ongoing topical glucocorticoids beyond 3 months, consider adding systemic immunomodulatory therapy to allow tapering of topical steroids 1
• For mild transient elevations of IOP, topical IOP-lowering medications can be used while continuing steroid therapy if necessary 2, 3
• For significant IOP elevation, add topical IOP-lowering medications, consider switching to a steroid with lower IOP risk, and consider surgical intervention in severe cases unresponsive to medical therapy 2, 3, 5

Treatment Algorithm for Steroid-Induced IOP Elevation

• For mild elevation (IOP 21-25 mmHg), continue monitoring closely and consider reducing steroid frequency if clinically appropriate 1
• For moderate elevation (IOP 26-35 mmHg), initiate topical IOP-lowering medication, reduce steroid frequency or switch to lower-potency steroid if possible, and re-evaluate within 1-2 weeks 2, 5, 7
• For severe elevation (IOP >35 mmHg), discontinue steroid if clinically feasible, initiate multiple topical IOP-lowering medications, consider oral carbonic anhydrase inhibitors for rapid IOP reduction, and refer urgently to glaucoma specialist 5, 7

Common Pitfalls and Caveats

• Continuing topical steroids beyond 3 months without considering alternative therapies increases risk of complications 1
• Using higher doses than necessary (≥4 drops daily) significantly increases the risk of complications 1
• Failing to monitor for IOP elevation during treatment 1

Prednisolone Acetate 1 % Dosing and Monitoring in Acute Anterior Uveitis

Initiation and Preferred Formulation

• For patients with acute anterior uveitis, start prednisolone acetate 1 % eye drops at a frequency of one drop every 1–2 hours while awake during the first week; this intensive regimen is recommended because prednisolone acetate provides superior corneal penetration compared with other topical corticosteroids. 8

Tapering, Duration Limits, and When to Add Systemic Therapy

• Taper the topical steroid as soon as the anterior‑chamber cellular reaction is controlled, aiming to discontinue the drops within three months to reduce the risk of steroid‑induced glaucoma and cataract formation. 8
• The total duration of prednisolone acetate therapy should not exceed three months; longer use markedly increases ocular complications. 8
• If a patient requires 1–2 drops per day for more than three months, systemic immunomodulatory therapy (e.g., methotrexate, adalimumab, or other disease‑modifying antirheumatic drugs) should be added to enable safe discontinuation of topical steroids. [8][9]

Dose‑Related Risk Thresholds

• Using ≥ 2 drops per day is a strong risk factor for intra‑ocular pressure (IOP) elevation, with the risk rising proportionally as dosing frequency increases. 8
• Administering ≥ 4 drops per day significantly raises the risk of cataract development compared with ≤ 3 drops per day. 8

Monitoring Schedule Based on Clinical Status

• During tapering of topical steroids, patients should undergo an ophthalmologic examination at least once per month. 9
• Patients who are stable on low‑dose therapy should have an eye exam at minimum every three months. 9

Alternative Potent Formulation (Difluprednate)

• Difluprednate 0.05 % is a more potent corticosteroid that permits less frequent dosing, improving patient compliance. 8
• However, difluprednate carries a higher risk of steroid‑induced IOP elevation and cataract formation than prednisolone acetate 1 %; therefore it should be reserved for cases that do not respond adequately to prednisolone acetate. 8

Safety Pitfalls to Avoid

• Do not continue topical steroids beyond three months without initiating systemic immunomodulatory therapy or having a clear discontinuation plan. 8
• Do not maintain a regimen of ≥ 4 drops daily for a prolonged period because of the dramatically increased cataract risk. 8
• Do not keep patients on 1–2 drops per day indefinitely without considering systemic therapy to mitigate long‑term steroid exposure. [8][9]